Medline ® Abstract for Reference 135
of 'Fluoropyrimidine-associated cardiotoxicity: Incidence, clinical manifestations, mechanisms, and management'
Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Wilson KS, Fitzgerald CA, Barnett JB, Gill S, Khoo KE
Cancer Invest. 2007;25(8):711.
BACKGROUND: Severe 5-FU toxicity in adjuvant therapy of colorectal cancer may require change of therapy. We retrospectively explored the safety and efficacy of adjuvant raltitrexed in patients intolerant of 5-FU.
METHODS: Over a 5 year period, patients who received 5-FU and subsequent raltitrexed therapy were identified.
RESULTS: There were 44 patients, (39 stage III). Median number of prior 5-FU cycles was 2. Three year relapse free and overall survival proportions for stage III patients were 70.8% and 83.6%, respectively.
CONCLUSIONS: Raltitrexed adjuvant therapy can be given safely and effectively in patients where further 5-FU is contraindicated.
Gastro-Intestinal Tumor Group, British Columbia Cancer Agency, Vancouver Island Centre, Victoria, British Columbia. KWilson@bccancer.bc.ca